In a phase 1/2 trial, the median survival of newly diagnosed glioblastoma patients who underwent radiation therapy with gefitinib, an EGFR inhibitor, was similar to the survival of the control group receiving radiation alone [8]. The gene discussed is EGFR; the disease is glioblastoma.